Oxaliplatin neurotoxicity;Neurotoxicité de l'oxaliplatine

Bulletin du Cancer

Volumn 93, Issue SPEC. ISS., 2006, Pages

  Gamelin, Laurence ^a   Boisdron Celle, Michèle ^b   Morel, Alain ^b   Gamelin, Érick ^b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b CENTRE PAUL PAPIN   (France)

Author keywords

Neurotoxicity; Oxaliplatin

Indexed keywords

AMIFOSTINE; ANTIOXIDANT; CALCIUM; GABAPENTIN; GLUTAMINE; GLUTATHIONE; MAGNESIUM; NERVE GROWTH FACTOR RECEPTOR; OXALIPLATIN; SODIUM CHANNEL; THIOCTIC ACID; TOCOPHEROL; VENLAFAXINE; VOLTAGE GATED SODIUM CHANNEL; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ATAXIA; CHELATION; CLINICAL FEATURE; DIGESTIVE SYSTEM TUMOR; DYSESTHESIA; FUNCTIONAL DISEASE; HUMAN; MUSCLE CONTRACTION; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; REVIEW; RIGIDITY; TOXICITY AND INTOXICATION;

ANTINEOPLASTIC AGENTS; HUMANS; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS;

EID: 33644872326     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Graham J, Mushin M, Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discov 2004; 3: 11-2.
2. Pendyala L, Creaven PJ, Perez R, Zdanowicz JR, Raghavan D. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother Pharmacol 1995; 36: 271-8.
3. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855-65.
4. Dunn TA, Schmoll HJ, Grunwald V, Bokemeyer C, Casper J. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997; 15: 109-14.
5. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother 2003; 4: 889-901.
6. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 2002; 42: 317-25.
7. Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29A: 1280-4.
8. Bugat R. Oxaliplatin tolerance in the treatment of metastatic colorectal cancers. Bull Cancer 2001; 88 (Spec): S45-9.
9. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
10. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004; 29: 387-92.
11. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002; 20: 1767-74.
12. Barchi RL. Ion channel mutations and diseases of skeletal muscle. Neurobiol Dis 1997; 4: 254-64.
13. Peltier AC, Russell JW. Recent advances in drug-induced neuropathies. Curr Opin Neurol 2002; 15: 633-8.
14. Garufi C, Pietrangeli A, Brienza S, et al. Electrophysiological evaluation of oxaliplatin neurotoxicity. Proc Am Soc Clin Oncol 1999; 18: abstr 938.
15. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001; 85: 2293-7.
16. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29: 21-33.
17. Boughattas N. Effects on anticancer agent oxaliplatin on the excitability properties of the peripheral nervous system. Proc Am Assoc Cancer Res 1994; 35: 433; abstr 2583.
18. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na (+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000; 406: 25-32.
19. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Mabro M, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (Folfox7). Eur J Cancer 2001; 37: 1000-5.
20. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997; 350: 681-6.
21. Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5 fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004; 10: 4055-61.
22. Lersch C, Schmelz R, Eckel F, Erdmann J, Mayr M, Schulte-Frohlinde E, et al. Prevention of oxaliplatin-induced peripheral sens. J Clin Oncol 2002; 7: 1767-74.
23. Durand JP, Brezault C, Goldwasser F. Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. Anticancer Drugs 2003; 14: 423-5.
24. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002; 20: 3478-83.
25. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann oncol 2001; 12: 421-2.
26. Gedlicka C, Scheithauer W, Schull B, Kornek GV. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002; 20: 3359-61.